Kamada Wins $10–$14 Million Extension of Canadian Plasma-Product Tender

Kamada ( (IL:KMDA) ) has shared an announcement.

On December 18, 2025, Kamada Ltd. announced it has secured a two-year extension to an existing Canadian Blood Services tender, covering four specialty plasma-derived products—WINRHO, HEPAGAM, CYTOGAM and VARIZIG—valued at $10 million to $14 million and expected to generate about $5 million to $7 million in annual sales between the second quarter of 2026 and the first quarter of 2028. Combined with continued Canadian sales of KAMRAB and Takeda-distributed GLASSIA, the award reinforces Kamada’s role as a leading supplier of specialty plasma-derived products in Canada and supports its reiterated 2025 guidance of $178 million to $182 million in revenue and $40 million to $44 million in adjusted EBITDA, underpinning management’s expectation of further growth from its commercial and biosimilar portfolios, expanded plasma sales and additional business development initiatives.

The most recent analyst rating on (IL:KMDA) stock is a Buy with a ILs13.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.

More about Kamada

Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies and marketed products for rare and serious conditions. Its portfolio includes six FDA-approved plasma-derived products, such as KEDRAB, CYTOGAM, GLASSIA, WINRHO SDF, VARIZIG and HEPAGAM B, as well as other immunoglobulin and anti-snake venom therapies, alongside a growing biosimilar distribution business in Israel. The company is also expanding its U.S. plasma collection network and leverages in-licensing, collaborations and M&A to broaden its product base, with FIMI Opportunity Funds as its controlling shareholder.

Average Trading Volume: 92,007

Technical Sentiment Signal: Buy

Current Market Cap: ILs1.33B

Find detailed analytics on KMDA stock on TipRanks’ Stock Analysis page.